We read with great interest the recent publication by Fehm and coworkers [1] about the association between the spread of circulating tumor cells (CTCs) and breast cancer subtypes. Th e authors observed that the highest CTC positivity rate was obtained in triple-negative patients followed by those with estrogen receptor (ER)positive and/or progesterone receptor (PR)-positive tumors, while no CTCs could be detected in the human epidermal growth factor receptor 2 (HER2)-positive subtype group. However, another study [2] showed contradictory results, indicating that HER2 was the only primary tumor characteristic that correlated with the presence of CTCs, while ER and PR status were not association with their presence.
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To clarify the correlation between CTCs and breast cancer subtypes, a total of 156 operable breast cancer patients admitted to our hospital were enrolled. Th is study was approved by the regional ethics committee. Written informed consent was obtained from all participating patients. Mononuclear cell enrichment and CTC detection were done as previously described [3] . Th e expression of ER, PR and HER2 in primary tumors was routinely detected.
Results showed that the overall positive rate of CTCs in operable breast cancer patients was 32.1% (50 out of 156). Th ere existed signifi cant diff erences in the positive rate of CTCs between patients at diff erent pTNM stages (P = 0.0219) and between those with diff erent immunohisto chemical subtypes (P = 0.0003). Further analysis revealed that the positive rate of CTCs in the HER2positive and triple-negative subtypes was signifi cantly higher than that of the luminal subtype (P = 0.0034 and 0.0003, respectively). In subgroup analysis by pTNM stage, signifi cant diff erences in the positive rate of CTCs between patients with diff erent breast cancer subtypes were identifi ed at stages I (P = 0.0207), II (P = 0.0478) and III (P = 0.0324) ( Table 1) , further supporting that the presence of CTCs was associated with the HER2-positive and triple-negative subtypes.
In the present study, the presence of CTCs was more frequently found in patients with HER2-positive and triple-negative subtypes than the luminal subtype, which might be ascribed to primary tumors of the former two subtypes being more aggressive histologically and having increased potential to be invasive, to migrate and to metastasize. In addition, recent research has suggested that the epithelial-mesenchymal transition plays a critical role in cancer progression, which could endow cancer cells with aggressive and stem cell-like properties, and pro mote the dissemination of CTCs from the primary site to the circulation [4] . Most importantly, it has been shown that CTCs could express epithelial-mesenchymal transi tion and/or cancer stem cell markers, which would support the hypothesis derived from the clinical data that CTCs are closely associated with distant metastasis in breast cancer patients [5] . Th erefore, all these observations further support the need to clarify the correlation of primary tumor characteristics and CTCs in breast cancer patients.
In conclusion, our study suggests that the spread of CTCs was correlated with the HER2-positive and triplenegative subtypes in breast cancer patients. Identifying 
